Geographic WeaknessNo major improvement has been seen in China, and none is expected until 2025.
Market PerformanceLife Sciences markets remain weak, with Instruments and select areas of consumables being challenged.
ValuationThe main concern is valuation, with shares trading at a 30% premium to Tools, near the Covid-era peak spread, making the risk/reward seem balanced.